Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: PuddleGlum who wrote (9261)	7/13/2005 4:34:46 PM
From: Galirayo	Respond to of 23958

Yep .. I'd say ARIA is ready for Lift Off. :) Well .. you Really need to Try that Papa Murphys. I will GARR AROUNT TEE you'll like. The Franchise Owner here was an Engineer. He knows how to put it all together. lol

To: PuddleGlum who wrote (9261)	8/18/2005 9:23:27 AM
From: Galirayo	Read Replies (1) \| Respond to of 23958

[ARIA] It's Ready again. stockcharts.com[w,a]dacayiay[db][pb50!c20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G Market Pulse: Ariad Pharma gets orphan-drug status for cancer drug Thursday August 18, 7:43 am ET By Thomas Middleton NEW YORK (MarketWatch) -- Ariad Pharmaceuticals Inc. said Thursday that AP23573, its novel mTOR inhibitor, has been designated an orphan drug by the Food and Drug Administration for the treatment of both soft-tissue and bone sarcomas. The Cambridge, Mass., company said its small-molecule drug starves cancer cells and shrinks tumors by inhibiting the critical cell-signaling protein, mTOR. Shares of Ariad last traded down 2.8% at $7.06.